Clinical Trial Detail

NCT ID NCT01753713
Title Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Case Comprehensive Cancer Center|Manmeet Ahluwalia, MD|National Cancer Institute (NCI)|Novartis
Indications

brain cancer

glioblastoma multiforme

gliosarcoma

Therapies

Dovitinib

Age Groups: adult

No variant requirements are available.